Valuation dashboard for Skye Bioscience, Inc. (SKYE) with P/E N/A, P/B 1.49, EV/EBITDA -0.44 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $1.70, SKYE has negative trailing earnings (P/E not meaningful) and an ROE of -279.29%. Market capitalisation stands at $7M.
Balance sheet quality for SKYE: current ratio of 3.3. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 1.49 |
| EV / EBITDA | -0.44 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $0.79 |
| vs Current Price | -53.8% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| SKYE | Skye Bioscience, Inc. | $7M | 1.49 | -279.3% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $1.70 |
| Market Cap | $7M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -279.29% |
| Return on Invested Capital | -286.55% |
| Return on Assets | -197.52% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALGS · BRNS · CVM · INMB · KZR · LVTX · MRSN
Explore sector: Healthcare · Biotechnology
More sections of SKYE: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks